N-Boc-Dap-6-aminoquinoIine | 1307229-35-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-Boc-Dap-6-aminoquinoIine
• 英文别名: tert-butyl (2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-(quinolin-6-ylamino)propyl]pyrrolidine-1-carboxylate
• CAS: 1307229-35-1
• 化学式: C₂₃H₃₁N₃O₄
• 分子量: 413.517
• InChiKey: GOCVAFUQPHSOMY-UIAACRFSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  30
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  80.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-Boc-Dap-6-aminoquinoIine 在 氰基磷酸二乙酯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 21.0h， 生成 auristatin-6-AQ
  参考文献：
  名称：

  Antineoplastic Agents. 592. Highly Effective Cancer Cell Growth Inhibitory Structural Modifications of Dolastatin 10

  摘要：

  The dolastatin series of unique peptides, originally discovered as constituents of the sea hare Dolabella auricularia, is of increasing importance in providing biological leads, especially to new and useful anticancer drugs. Dolastatin 10 and three analogues, minor structural modifications designated auristatins, are currently in human cancer clinical trials. The present study was undertaken to explore delivery to the cancer sites by way of phosphate or quinoline modifications. The initial objectives, auristatin TP as sodium phosphate 3b (GI(50) 10(-2)-10(-4) mu g/mL), auristatin 2-AQ (4, GI(50) 10(-2)-10(-3) mu g/mL), and auristatin 6-AQ(5, GI(50) 10(-4) mu g/mL), exhibited superior cancer cell growth inhibitory properties.

  DOI：

  10.1021/np1007334
• 作为产物：
  描述：

  ((2R,3R)-3-((S)-1-(tert丁氧基羰基)吡咯烷-2-基)-3-甲氧基-2-甲基丙酸 在 吡啶 、 三聚氟氰 作用下， 以 吡啶 、 二氯甲烷 为溶剂， 反应 41.0h， 生成 N-Boc-Dap-6-aminoquinoIine
  参考文献：
  名称：

  [EN] AURISTATIN TYRAMINE PHOSPHATE SALTS AND AURISTATIN AMINOQUINOLINE DERIVATIVES AND PRODRUGS THEREOF
  [FR] SELS DE TYRAMINE PHOSPHATE D'AURISTATINE ET DÉRIVÉS D'AMINOQUINOLÉINE D'AURISTATINE ET PROMÉDICAMENTS DE CEUX-CI

  摘要：

  本发明涉及新的奥利斯泰汀化合物及其前药，包含它们的组合物和用途。

  公开号：

  WO2012135440A1

文献信息

• [EN] AURISTATIN TYRAMINE PHOSPHATE SALTS AND AURISTATIN AMINOQUINOLINE DERIVATIVES AND PRODRUGS THEREOF<br/>[FR] SELS DE TYRAMINE PHOSPHATE D'AURISTATINE ET DÉRIVÉS D'AMINOQUINOLÉINE D'AURISTATINE ET PROMÉDICAMENTS DE CEUX-CI
  申请人：UNIV ARIZONA

  公开号：WO2012135440A1

  公开（公告）日：2012-10-04

  The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.

  本发明涉及新的奥利斯泰汀化合物及其前药，包含它们的组合物和用途。
• AURISTATIN TYRAMINE PHOSPHATE SALTS AND AURISTATIN AMINOQUINOLINE DERIVATIVES AND PRODRUGS THEREOF
  申请人：Pettit George R.

  公开号：US20140023666A1

  公开（公告）日：2014-01-23

  The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.

  本发明涉及新的奥利司他类化合物及其前药，包括它们的组合物和用途。
• US9044518B2
  申请人：——

  公开号：US9044518B2

  公开（公告）日：2015-06-02
• US9539342B2
  申请人：——

  公开号：US9539342B2

  公开（公告）日：2017-01-10
• Antineoplastic Agents. 592. Highly Effective Cancer Cell Growth Inhibitory Structural Modifications of Dolastatin 10
  作者：George R. Pettit、Fiona Hogan、Steven Toms

  DOI：10.1021/np1007334

  日期：2011.5.27

  The dolastatin series of unique peptides, originally discovered as constituents of the sea hare Dolabella auricularia, is of increasing importance in providing biological leads, especially to new and useful anticancer drugs. Dolastatin 10 and three analogues, minor structural modifications designated auristatins, are currently in human cancer clinical trials. The present study was undertaken to explore delivery to the cancer sites by way of phosphate or quinoline modifications. The initial objectives, auristatin TP as sodium phosphate 3b (GI(50) 10(-2)-10(-4) mu g/mL), auristatin 2-AQ (4, GI(50) 10(-2)-10(-3) mu g/mL), and auristatin 6-AQ(5, GI(50) 10(-4) mu g/mL), exhibited superior cancer cell growth inhibitory properties.